Healthcare & Biotech

SHERIDAN, WYOMING -- June 9, 2026 -- Philips has put its VeriSight Pro 3D intracardiac echocardiography (ICE) technology in front of a wider audience through a feature on the BBC's technology program Tech Now, filmed during a live structural heart procedure in Copenhagen. The technology places a miniature ultrasound probe on the tip of a catheter, threading it through a vein into the heart to deliver real-time three-dimensional images of anatomy, valves, and treatment devices. For interventional teams, it offers an alternative to passing a larger probe down the patient's esophagus under general anaesthesia. The result is a more precise and less invasive route to treating structural heart disease.

SHERIDAN, WYOMING -- June 9, 2026 -- Philips has released its Future Health Index 2026, the 11th edition of its annual global study, drawing on responses from more than 2,000 healthcare professionals and over 20,000 patients across 10 countries. The findings show that artificial intelligence already saves clinicians the equivalent of more than 16 working days each year and is helping many of them treat additional patients. At the same time, the report warns that inadequate training and fragmented IT infrastructure could leave some health systems behind. For hospital leaders and care providers, the results frame AI less as a future prospect and more as an operational tool already reshaping daily workloads.

SHERIDAN, WYOMING -- June 7, 2026 -- Ivoclar has published clinical practice guidance for dental professionals working with the Tetric plus composite system, focusing on combined workflows involving Tetric plus Flow and Tetric plus Fill in anterior restorations. The guidance positions Tetric plus Flow as a single-material replacement for both Tetric EvoFlow and Tetric PowerFlow, built around its thixotropic properties — controlled, precise application alongside strong flow when required. Three tips address contouring support, surface imperfection repair and volume or transition adjustment in Class IV, Class V and direct veneer procedures. OptraSculpt Pad and OptraGloss are recommended as supporting instruments throughout.

SHERIDAN, WYOMING -- June 6, 2026 -- Henry Schein, Inc. has elected William K. "Dan" Daniel as Independent Chairman of the Board effective May 21, 2026, as Stanley M. Bergman steps down following 44 years as a Director of the company. Daniel joined the Henry Schein board in May 2025 and brings executive leadership experience across healthcare and industrial businesses, including a 14-year tenure as Executive Vice President at Danaher Corporation. The election places a leader with direct experience in dental sector governance and operations in the chair role at the world's largest provider of healthcare solutions to office-based dental and medical practitioners. Bergman has been named Chairman Emeritus.

SHERIDAN, WYOMING - May 19, 2026 - Dentsply Sirona has announced that its Primescan 2 Cart has received the 2026 iF Design Award in the Product Design - Medicine / Health category, recognizing its ergonomic engineering, clinician-focused usability, and integration into cloud-based digital dental workflows. The award highlights the system's role in supporting more mobile, connected intraoral scanning environments as digital dentistry adoption continues to expand globally. The recognition also reflects increasing industry emphasis on workflow efficiency, portability, and system integration within modern dental practices transitioning toward cloud-native clinical infrastructure.

SHERIDAN, WYOMING - May 19, 2026 - Royal Philips has introduced SmartIQ, a new coronary imaging technology integrated into its Azurion image-guided therapy platform, designed to address a long-standing clinical challenge in interventional cardiology: balancing high image quality with reduced radiation exposure. The system was developed with cardiovascular centers and focuses on ultra-low dose imaging protocols that maintain diagnostic clarity while lowering X-ray exposure for patients and clinical staff. Philips is positioning the technology as part of a broader strategy to strengthen workflow consistency, evidence generation, and dose optimization in coronary procedures, with initial clinical validation already underway through published pilot studies and ongoing multicenter research programs.

SHERIDAN, WYOMING - May 19, 2026 - Royal Philips is using EuroPCR 2026 in Paris to present an expanded portfolio of imaging, physiology and AI-enabled workflow technologies aimed at supporting increasingly complex percutaneous coronary intervention (PCI) and structural heart procedures. The company's latest developments focus on integrating imaging systems, physiological assessment tools and procedural guidance into a unified interventional cardiology workflow while also addressing radiation exposure concerns in catheterization laboratories. Philips is positioning the strategy around operational efficiency, procedural confidence and lower-dose imaging as healthcare providers manage rising procedural complexity and increased pressure on cath lab performance.

SHERIDAN, WYOMING - May 13, 2026 - Dentsply Sirona and the American Association for Dental, Oral, and Craniofacial Research (AADOCR) have announced the winners of the 2026 Student Competition for Advancing Dental Research and its Application (SCADA) Awards, recognizing pre-doctoral dental students for research excellence across clinical and basic science disciplines. The awards were presented during the 55th Annual Meeting of AADOCR, held in conjunction with the 104th General Session and Exhibition of the IADR and the 50th Annual Meeting of the Canadian Association for Dental Research, at the San Diego Convention Center from March 25 to 28, 2026. This year's competition drew 61 dental students from across the United States and seven international finalists from Canada, France, Thailand, Taiwan, South Korea, and Japan.

SHERIDAN, WYOMING - May 13, 2026 - Roche has received CE Mark for Elecsys® pTau217, a blood-based diagnostic test designed to detect amyloid pathology associated with Alzheimer's disease, developed in collaboration with Eli Lilly and Company. The test measures phosphorylated Tau 217 protein from a routine blood draw and is intended to rule in or rule out amyloid pathology across both primary and secondary care settings using a single-assay design with unified cutoffs. The regulatory clearance positions Elecsys® pTau217 for deployment across Roche's installed base of laboratory instruments in CE mark-accepting countries, with potential FDA clearance in the United States under consideration for later this year.

SHERIDAN, WYOMING - May 13, 2026 - TuHURA Biosciences, Inc. (NASDAQ: HURA), a Phase 3 immuno-oncology company focused on overcoming resistance to cancer immunotherapy, has confirmed that President and Chief Executive Officer James A. Bianco, M.D., will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference in New York City on May 19, 2026, at 2:00 pm ET. The appearance gives institutional investors and sector analysts direct access to leadership at a moment when TuHURA is running an active Phase 3 registration trial and advancing two additional pipeline programs. For stakeholders tracking immuno-oncology development timelines and clinical positioning, the session represents a structured opportunity to assess the company's near-term milestones.